While it's not ready to join the workforce yet, Atlas, an AI-powered humanoid, is learning how to do human tasks.

Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...

Many projects on these pages do clever things with video. Whether it’s digital or analogue, it’s certain our community can ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...

・Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option. ・H.C.